BIOSYNTH
9.5.2023 11:01:34 CEST | Business Wire | Press release
Biosynth, a supplier of critical raw materials to the life science industry, announces today that it has acquired Cambridge Research Biochemicals (“CRB”), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.
CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.
Dr. Urs Spitz, CEO and President of Biosynth, said, “CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division. Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.”
“We are excited to be joining the Biosynth family”, added Emily Humphrys, Managing Director of Cambridge Research Biochemicals. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”
--ends--
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About Cambridge Research Biochemicals
Cambridge Research Biochemicals (www.crbdiscovery.com) is a leading independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 10:11:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 10:06:00 CEST | Press release
Joint achievement highlights how Analog In-Memory Computing can address the growing energy and thermal challenges of AI while laying the foundation for deeper collaboration on next-generation memory and computing architectures. TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technolo
Vultr and SUSE Launch Validated Full-Stack NVIDIA Enterprise AI Platform to Accelerate Production Deployments8.7.2026 10:00:00 CEST | Press release
SUSE AI Factory with NVIDIA on Vultr Infrastructure delivers integrated enterprise AI software, GPU acceleration, and global cloud infrastructure to move organizations from AI experimentation to secure production Vultr, the world's largest privately-held cloud infrastructure company, today announced the launch of SUSE AI Factory with NVIDIA on Vultr infrastructure, developed in partnership with SUSE. Announced alongside SUSE at the RAISE Summit in Paris, this validated, full-stack enterprise AI platform combines enterprise-grade AI software, advanced GPU acceleration, and global AI infrastructure into a single, production-ready solution. As organizations look to move AI workloads from experimentation into production, this joint solution eliminates the complexity of building AI stacks from scratch, allowing enterprises to deploy secure, scalable AI applications with ease. The solution combines software and infrastructure capabilities to help organizations securely and reliably advance a
NetApp Named Presenting Partner of 2026 NFL Madrid Game8.7.2026 10:00:00 CEST | Press release
League’s Official Intelligent Data Infrastructure Partner Extends Its Presence Across the NFL’s International Games The NFL today announced that the league’s Global Partner, NetApp (NASDAQ: NTAP), the Intelligent Data Infrastructure company, will return as Presenting Partner of the 2026 NFL Madrid Game, featuring the Atlanta Falcons taking on the Cincinnati Bengals at the Bernabéu Stadium — home to Real Madrid C.F. — on Sunday, Nov. 8. The multi-year announcement builds on NetApp’s role as the league’s Official Intelligent Data Infrastructure Partner and Presenting Partner of the inaugural NFL Madrid Game in 2025 and continues the company’s support of the league’s international games. “We are delighted to welcome NetApp back as Presenting Partner of the NFL Madrid Game,” said Rafa De Los Santos, country manager of NFL Spain. “Last year’s game at the Bernabéu was a landmark moment for the NFL in Spain, and with the Falcons and Bengals bringing two of the most exciting teams in football
MSIG Europe Selects Clearwater Analytics to Modernize Investment Operations8.7.2026 10:00:00 CEST | Press release
Selection extends MS&AD Group’s global relationship with Clearwater, bringing a unified platform for investment data, accounting, regulatory reporting, and analytics to MSIG Europe Clearwater Analytics today announced that MSIG Europe, a wholly owned subsidiary of MS&AD Insurance Group, has selected the Clearwater platform to modernize its operating model, unify data across the investment lifecycle, and meet the demands of the European regulatory environment, including Belgian GAAP, IFRS and Solvency II. European insurers are navigating the convergence of tightening regulatory demands, growing allocations to private markets, and the operational limits of fragmented legacy systems. The firms moving fastest are consolidating onto platforms that deliver daily accuracy, compliance automation, and integrated analytics at scale. MSIG is a wholly-owned subsidiary of Mitsui Sumitomo Insurance and a member of the MS&AD Insurance Group, one of Asia’s leading non-life insurance brands with a pres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom